2025
Severe Hypercalcemia Associated With Perinatal Hypophosphatasia While Receiving Enzyme Replacement Therapy
Salama M, Al Nofal A, Tebben P. Severe Hypercalcemia Associated With Perinatal Hypophosphatasia While Receiving Enzyme Replacement Therapy. JCEM Case Reports 2025, 3: luaf066. PMID: 40236614, PMCID: PMC11997545, DOI: 10.1210/jcemcr/luaf066.Peer-Reviewed Original ResearchTissue-nonspecific alkaline phosphataseSevere hypercalcemiaCalcium intakeAA doseAsfotase alfaPerinatal hypophosphatasiaMonitoring of calcium levelsRestricted calcium intakeDefective bone mineralizationDietary calcium restrictionFunction of tissue-nonspecific alkaline phosphataseEnzyme replacement therapyCalcitonin therapyCalcium restrictionReplacement therapyDietary intakeHypercalcemiaIntravenous fluidsCalcium levelsMaintenance of calciumGene variantsHypophosphatasiaInfantile formHospital admissionBone mineralization
2024
An infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk
Salama M, Tebben P, Al Nofal A. An infant developing hypercalcemia and hypophosphatemia due to the use of exclusively almond milk. Journal Of Pediatric Endocrinology And Metabolism 2024, 37: 375-379. PMID: 38414167, DOI: 10.1515/jpem-2023-0494.Peer-Reviewed Case Reports and Technical NotesConceptsParathyroid hormoneCreatinine ratioUrine calcium-to-creatinine ratioHistory of biliary atresiaCalcium to creatinine ratioMonths prior to presentationAlmond milkCow's milk allergyMilk consumptionMonths of ageSevere hypercalcemiaBiliary atresiaAlternative to cow milkCow's milkD levelsLiver transplantationPlant-based milk alternativesCase reportInitial managementIntravenous fluidsMilk allergyHypercalcemiaMineral contentCalcium concentrationHypophosphatemia
2023
THU461 Severe Hypercalcemia Associated With Perinatal Hypophosphatasia While Receiving Enzyme Replacement Therapy
Salama M, Tebben P. THU461 Severe Hypercalcemia Associated With Perinatal Hypophosphatasia While Receiving Enzyme Replacement Therapy. Journal Of The Endocrine Society 2023, 7: bvad114.422. PMCID: PMC10555444, DOI: 10.1210/jendso/bvad114.422.Peer-Reviewed Original ResearchDietary calcium intakeCalcium intakeAsfotase alfaPerinatal hypophosphatasiaMonths of ageTissue non-specific alkaline phosphataseSevere hypercalcemiaAA doseIncreased to 3 mg/kgLow calcium intakeDefective bone mineralizationLong-term therapyEnzyme replacement therapyTreated with AAPrenatal ultrasoundCalcitonin therapyPersistent hypercalcemiaInitial presentationAA therapyHydroxyvitamin DNon-specific alkaline phosphataseCalcium supplementationParathyroid hormoneReplacement therapyInitial management
2017
Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia
Patel N, Carpenter T, Genel M. Single Dose Of Bisphosphonate To Treat Infantile Hypercalcemia. AACE Clinical Case Reports 2017, 3: e246-e250. DOI: 10.4158/ep161536.cr.Peer-Reviewed Original ResearchSubcutaneous fat necrosisSingle doseSevere hypercalcemiaDihydroxyvitamin DParathyroid hormonePTH parathyroid hormoneLife-threatening complicationsTreatment of hypercalcemiaLow calcium dietWeeks of lifePosterior upper armPg/mLAggressive hydrationTerm neonatesCalcium dietConfluent plaquesRadiologic findingsFat necrosisTreatment courseTherapeutic coolingSubsequent hypercalcemiaHypercalcemiaInfantile hypercalcemiaCalcium levelsPg/
2010
Severe Hypercalcemia due to Primary Hyperparathyroidism with MEN 2A
Thompson G, Dy B, Vazquez B, Tebben P, Kumar S. Severe Hypercalcemia due to Primary Hyperparathyroidism with MEN 2A. World Journal Of Endocrine Surgery 2010, 2: 131-133. DOI: 10.5005/jp-journals-10002-1037.Peer-Reviewed Original ResearchSevere hypercalcemia due to primary hyperparathyroidismHypercalcemia due to primary hyperparathyroidismPrimary hyperparathyroidismSevere hypercalcemiaParathyroid adenomaMEN 2ASurgical managementRare presentation of primary hyperparathyroidismCalcium levelsPresentation of primary hyperparathyroidismDecreased bone mineral densityElevation of serum calciumSingle parathyroid adenomaTreatment of hyperparathyroidismEarly surgical managementBone mineral densityTime of diagnosisParathyroid carcinomaRare presentationClinical presentationSerum calciumMineral densitySevere elevationClinical manifestationsDifferential diagnosis
1984
Hypercalcemia associated with immunoreactive parathyroid hormone in a malignant rhabdoid tumor of the kidney (Rhabdoid Wilms' tumor)
Mayes L, Kasselberg AG, Roloff J, Lukens J. Hypercalcemia associated with immunoreactive parathyroid hormone in a malignant rhabdoid tumor of the kidney (Rhabdoid Wilms' tumor). Cancer 1984, 54: 882-884. PMID: 6331631, DOI: 10.1002/1097-0142(19840901)54:5<882::aid-cncr2820540521>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsImmunoreactive parathyroid hormoneParathyroid hormoneRhabdoid tumorElevated serum concentrationsNormal parathyroid glandsMalignant rhabdoid tumorMetabolic complicationsSevere hypercalcemiaMetastatic diseaseSerum concentrationsParathyroid glandsSkeletal involvementImmunohistologic demonstrationTumor variantsHypercalcemiaTumorsTumor cellsHormoneKidneyComplicationsDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply